Remimazolam mitigates cerebral ischemia/reperfusion injury by concurrently alleviating damage to the blood-brain barrier and RIP3/MLKL-driven necroptosis
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116182 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Zhihui Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province 210008, PR China. Hauptthemen laut MEDLINE: Reperfusion Injury, Blood-Brain Barrier, Neuroprotective Agents, Brain Ischemia. Die Arbeit nennt 57 Literaturangaben. Gefördert von: General Hospital of Eastern Theatre Command, National Natural Science Foundation of China.
Abstract (Originalsprache)
The pathogenesis of cerebral ischemia-reperfusion injury centers on neuroinflammation and oxidative stress-induced programmed cell death. Although remimazolam(REM) is a clinically used benzodiazepine sedative, its neuroprotective effects against various cell death modalities remain incompletely characterized. Cerebral ischemia-reperfusion injury induced significant cerebral edema, marked oxidative stress, elevated inflammatory factor expression, and substantial blood-brain barrier disruption. REM treatment significantly improved neurological deficits, reduced cerebral infarction volume, enhanced ZO-1 and occludin expression in the cerebral cortex, decreased Evans blue leakage, protected blood-brain barrier integrity, In the hippocampus, REM treatment also significantly inhibited neuroinflammation and oxidative stress, lowered pro-inflammatory factors (TNF-α and IL-1β), mitigated ROS-induced damage, blocked NLRP3 inflammasome activation, suppressed caspase-1 cleavage and GSDMD channel formation, downregulated RIP3/MLKL expression, reduced necroptosis, and improved motor function in rats. REM ameliorates cerebral ischemia-reperfusion injury through dual inhibition of the neuroinflammatory-oxidative stress cascade and concurrent blockade of both NLRP3/GSDMD-mediated pyroptosis and RIP3/MLKL-driven necroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province 210008, PR China.
- Department of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province 210008, PR China. Electronic address: chenghao927@126.com.
- Department of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province 210008, PR China. Electronic address: xjl15950466318@163.com.
- Department of Anesthesiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province 210008, PR China. Electronic address: qing_ji@nju.edu.cn.
Förderung
- General Hospital of Eastern Theatre Command
- National Natural Science Foundation of China
Zitieren
APA
Wang, Z., Zhang, R., Dai, D., Zhang, M., Gao, D., Zhang, J., Wu, Z., Hui, K., Xiong, J., Cheng, H., Xu, J., & Ji, Q. (2026). Remimazolam mitigates cerebral ischemia/reperfusion injury by concurrently alleviating damage to the blood-brain barrier and RIP3/MLKL-driven necroptosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116182
Vancouver
Wang Z, Zhang R, Dai D, Zhang M, Gao D, Zhang J, et al. Remimazolam mitigates cerebral ischemia/reperfusion injury by concurrently alleviating damage to the blood-brain barrier and RIP3/MLKL-driven necroptosis. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116182
BibTeX
@article{Wang2026,
author = {Wang, Zhihui and Zhang, Ruikun and Dai, Dong and Zhang, Meiling and Gao, Dapeng and Zhang, Jie and Wu, Zhifang and Hui, Kangli and Xiong, Jingwei and Cheng, Hao and Xu, Jiali and Ji, Qing},
title = {Remimazolam mitigates cerebral ischemia/reperfusion injury by concurrently alleviating damage to the blood-brain barrier and RIP3/MLKL-driven necroptosis},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116182}
}
EUVIMED